Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efalizumab + infliximab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of two biologic agents: efalizumab and infliximab. Efalizumab is a humanized monoclonal CD11a-antibody that was used for treating chronic plaque psoriasis. Infliximab is a TNF-α inhibitor (monoclonal antibody) used for treating various inflammatory conditions including Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. This combination has been studied in the treatment of palmoplantar pustular psoriasis and other inflammatory conditions.
02
Targets
ITGAL (Integrin alpha L (CD11a))TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on efalizumab + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efalizumab + infliximab.